5 Fatty Liver Subtypes Could Change How Doctors Assess Risk

Two people can receive the same fatty liver diagnosis but face very different health risks. One may have a relatively mild condition, while another could be more vulnerable to serious liver damage, heart disease or other complications. Scientists at Mayo Clinic have now identified five biologically distinct subtypes of metabolic dysfunction-associated steatotic liver disease (MASLD), offering a new way to understand why the disease progresses differently from person to person. The discovery could help doctors identify high-risk patients earlier, even when traditional warning signs are missing.





Fatty liver disease is often treated as one condition, but new research suggests its underlying biology is more complex. The Mayo Clinic team, working with Virginia Tech researchers, studied more than 4,600 people with MASLD using genetic information and clinical records. They identified five distinct biological groups with different characteristics and potential health outcomes. The study, published in Nature Communications, could help explain why some patients develop serious complications while others do not. However, these research-defined subtypes are not yet routine categories used in everyday clinical diagnosis.





MASLD develops when excess fat accumulates in the liver in association with metabolic dysfunction. It is often linked to obesity, insulin resistance, type 2 diabetes and abnormal cholesterol levels. The condition may cause no obvious symptoms, which means people can have it without realising it. In some cases, the disease progresses to inflammation and fibrosis, or scarring of the liver. Advanced fibrosis can lead to cirrhosis and increase the risk of liver cancer. This is why a lack of symptoms does not always mean the liver is healthy.

One of the study’s most important findings involved genetic forms of fatty liver disease. Some subtypes were associated with a greater likelihood of developing advanced liver damage, even among people who lacked common metabolic risk factors. This challenges the assumption that fatty liver risk can always be judged by body weight or diabetes status alone. Genetics is only one part of the picture, and the findings do not mean that everyone with a family history will develop severe disease. They suggest that doctors may eventually need more detailed information to assess individual risk.

The study found that the biological differences between MASLD subtypes may extend beyond the liver. Researchers identified associations between particular subtypes and conditions such as depression, sleep apnoea and migraine. These findings do not prove that fatty liver directly causes these conditions. Instead, they suggest that shared biological processes may connect liver health with other parts of the body. MASLD is also associated with an increased risk of cardiovascular problems and advanced liver disease. Understanding these links may help doctors assess a patient’s overall health rather than focusing only on liver fat.

Today, treatment decisions for fatty liver disease generally depend on factors such as liver damage, metabolic health, weight, diabetes and other medical conditions. The new findings could eventually help doctors go further by identifying the biological processes driving each patient’s disease. This may improve screening and help clinicians recognise people who need closer monitoring. Researchers also plan to investigate whether the different subtypes respond differently to existing treatments, including certain medicines used for diabetes and obesity. More studies are needed before subtype-based treatment becomes part of routine care.

Although scientists continue to study the different subtypes, several practical steps can support liver health. Eat balanced meals, limit sugary drinks and highly processed foods, stay physically active and work towards a healthy weight if needed. If you have diabetes, high cholesterol or high blood pressure, managing these conditions can also help reduce metabolic risks. Avoid alcohol if your doctor advises complete abstinence, particularly if liver damage is present. If you have been diagnosed with fatty liver, ask your healthcare professional whether blood tests or additional assessments are needed to check for fibrosis. Do not start supplements or medicines without medical advice.

The discovery of five MASLD subtypes is an important step towards understanding why fatty liver disease affects people differently. However, it does not mean that everyone needs genetic testing or that doctors can already identify these five groups through a routine scan. The research needs further validation in larger and more diverse populations. For now, people with fatty liver should focus on medical follow-ups, managing metabolic conditions and checking for signs of liver scarring when recommended. Early assessment can help identify people who need closer care before serious complications develop.

Fatty liver disease may look similar on the surface, but its underlying causes and long-term risks can differ. The Mayo Clinic study offers new evidence that genetic and clinical information may help explain these differences. Its findings could eventually lead to more personalised screening and treatment, particularly for people whose risk is not obvious from their weight or metabolic health. Until then, the best approach is to take a fatty liver diagnosis seriously, follow medical advice and manage the factors that can worsen liver health. A condition that causes few symptoms still deserves attention.


Experiencing frequent stress, fatigue, or health challenges? Your name energy may be worth exploring. Check it here.


Unlock insightful tips and inspiration on personal growth, productivity, and well-being. Stay motivated and updated with the latest at My Life XP.